SEARCH

SEARCH BY CITATION

References

  • Anderson, D.R., Grillo-Lopez, A., Varns, C., Chambers, K.S. & Hanna, N. (1997) Targeted anti-cancer therapy using rituximab, a chimeric anti-CD20 antibody (IDEC-C2B8) in the treatment of non-Hodgkin's B-cell lymphoma. Biochemical Society Transactions, 25, 705708.
  • Bindon, C.I., Hale, G. & Waldmann, H. (1988) Importance of antigen specificity for complement-mediated lysis by monoclonal antibodies. European Journal of Immunology, 18, 15071514.
  • Burton, D.R. & Woof, J.M. (1992) The human antibody effector function. Advances in Immunology, 51, 150.
  • Carbone, A., Gaidano, G., Gloghini, A., Pastore, C., Saglio, G., Tirelli, U., Dalla-Favera, R. & Falini, B. (1997) BCL-6 protein expression in AIDS-related non-Hodgkin's lymphomas. American Journal of Pathology, 150, 155165.
  • Coiffier, B., Lepage, E., Briere, J., Herbrecht, R., Tilly, H., Bouabdallah, R., Van den Morel, P.B., Neste, E., Salles, G., Gaulard, P., Reyes, F. & Gisselbrecht, C. (2002) CHOP chemotherapy plus rituximab compared to chop alone in elderly patients with diffuse large B cell lymphoma. New England Journal of Medicine, 346, 235242.
  • Corbellino, M., Bestetti, G., Scalamogna, C., Calattini, S., Galazzi, M., Meroni, L., Manganaro, D., Fasan, M., Moroni, M., Galli, M. & Parravicini, C. (2001) Long-term remission of Kaposi sarcoma-associated herpesvirus-related multicentric Castleman's disease with anti-CD20 monoclonal antibody therapy. Blood, 98, 34733475.
  • Czuczman, M.S. (1999) CHOP plus rituximab chemoimmunotherapy of indolent B-cell lymphoma. Seminars in Oncology, 26, 8896.
  • Czuczman, M., Fallon, A., Scarpace, A., Stewart, C., Bernstein, Z.P., MacCarthy, P., Skipper, M., Brown, K., Miller, K., Wentling, D., Rock, M.K., Benyunes, M. & Grillo-Lopez, A. (2000) Phase II study of Rituximab in combination with Fludarabine in patients (pts) with low grade or follicular B cell lymphoma. Blood, 96, 729a.
  • Dal Maso, L., Serraino, D. & Franceschi, S. (2001) Epidemiology of AIDS-related tumours in developed and developing countries. European Journal of Cancer, 37, 11881201.
  • Di Gaetano, N., Xiao, Y.M., Erba, E., Bassan, R., Rambaldi, A., Golay, J. & Introna, M. (2001) Synergism between fludarabine and rituximab revealed in a follicular lymphoma cell line resistant to the cytotoxic activity of either drug alone. British Journal of Haematology, 114, 111.
  • Drexler, H.G., Uphoff, C.C., Gaidano, G. & Carbone, A. (1998) Lymphoma cell lines: in vitro models for the study of HHV-8+ primary effusion lymphomas (body cavity-based lymphomas). Leukemia, 12, 15071517.
  • Dyer, M.J.S. (1999) The role of Campath-1 antibodies in the treatment of lymphoid malignancies. Seminars in Oncology, 26, 5257.
  • Epstein, A.L., Levy, R., Kim, H., Henle, W., Henle, G. & Kaplan, H.S. (1978) Biology of the human malignant lymphomas. IV. Functional characterisation of ten diffuse histiocytic lymphoma cell lines. Cancer, 42, 23792391.
  • Faye, A., Van den Abeele, T., Peuchmaur, M., Mathieu-Boue, A. & Vilmer, E. (1998) Anti-CD20 monoclonal antibody for post-transplant lymphoproliferative disorders. Lancet, 352, 1285.
  • Foran, J.M., Rohatiner, A.Z., Cunningham, D., Popescu, R.A., Solal-Celigny, P., Ghielmini, M., Coiffier, B., Johnson, P.W., Gisselbrecht, C., Reyes, F., Radford, J.A., Bessell, E.M., Souleau, B., Benzohra, A. & Lister, T.A. (2000) European phase II study of rituximab (chimeric anti-CD20 monoclonal antibody) for patients with newly diagnosed mantle-cell lymphoma and previously treated mantle-cell lymphoma, immunocytoma, and small B-cell lymphocytic lymphoma. Journal of Clinical Oncology, 18, 317324.
  • Gaidano, G. & Carbone, A. (2001) Primary effusion lymphoma. A liquid phase lymphoma of fluid-filled body cavities. Advances in Cancer Research, 80, 115146.
  • Gaidano, G., Parsa, N.Z., Tassi, V., Della-Latta, P., Chaganti, R.S.K., Knowles, D.M. & Dalla-Favera, R. (1993) In vitro establishment of AIDS-related lymphoma cell lines: phenotypic characterization, oncogene and tumor suppressor gene lesions, and heterogeneity in Epstein–Barr virus infection. Leukemia, 7, 16211629.
  • Gaidano, G., Capello, D. & Carbone, A. (2000) The molecular basis of AIDS-related lymphomagenesis. Seminars in Oncology, 27, 431441.
  • Ganser, A., Carlo-Stella, C., Bartram, C.R., Boehm, Th, Heil, G., Henglein, B., Müller, H., Raghavachar, An., Von Briesen, H., Griesinger, F., Völkers, B., Ruebsamen-Weigmann, H., Helm, E.B. & Hoelzer, D. (1988) Establishment of two Epstein–Barr virus negative Burkitt cell lines from a patient with AIDS and B-cell lymphoma. Blood, 72, 12551260.
  • Golay, J., Zaffaroni, L., Vaccari, T., Lazzari, M., Borleri, G.M., Bernasconi, S., Tedesco, F., Rambaldi, A. & Introna, M. (2000) Biologic response of B lymphoma cells to anti-CD20 monoclonal antibody rituximab in vitro: CD55 and CD59 regulate complement-mediated cell lysis. Blood, 95, 39003908.
  • Golay, J., Lazzari, M., Facchinetti, V., Bernasconi, S., Borleri, G., Barbui, T., Rambaldi, A. & Introna, M. (2001) CD20 levels determine the in vitro susceptibility to rituximab and complement of B-cell chronic lymphocytic leukaemia: further regulation by CD55 and CD59. Blood, 98, 33833389.
  • Greenwood, J., Clark, M. & Waldmann, H. (1993) Structural motifs involved in human IgG antibody effector functions. European Journal of Immunology, 23, 10981104.
  • Hale, G., Xia, M.Q., Tighe, M.J.S. & Waldmann, H. (1990) The Campath-1H antigen (CDw52). Tissue Antigens, 35, 118127.
  • Idusogie, E.E., Wong, P.Y., Presta, L.G., Gazzano-Santoro, H., Totpal, K., Ultsch, M. & Mulkerrin, M.G. (2001) Engineered antibodies with increased activity to recruit complement. Journal of Immunology, 166, 25712575.
  • Keating, M.J., O'Brien, S. & Albitar, M. (2002) Emerging information on the use of Rituximab in chronic lymphocytic leukemia. Seminars in Oncology, 29, 7074.
  • Knowles, D.M. & Pirog, E.C. (2001) Pathology of AIDS-related lymphomas and other AIDS-defining neoplasms. European Journal of Cancer, 37, 12361250.
  • Knowles, D.M., Chamulak, G.A., Subar, M., Pelicci, G., Dugan, M.J.S.B., Raphael, B. & Dalla-Favera, R. (1988) Clinicopathologic, immunophenotypic and molecular genetic analysis of AIDS-associated lymphoid neoplasia: clinical and biologic implication. Pathology Annual, 23, 3367.
  • Liszewski, M., Farries, T.C., Lublin, D.M., Rooney, I.A. & Atkinson, J.P. (1996) Control of the complement system. Advances in Immunology, 61, 201279.
  • Lundin, J., Oesterborg, A., Brittinger, G., Crowther, D., Dombret, H., Engert, A., Epenetos, A., Gisselbrecht, C., Huhn, D., Jaeger, U., Thomas, J., Marcus, R., Nissen, N., Poynton, C., Rnakin, E., Stahel, R., Uppenkamp, M., Willemze, R. & Mellstedt, H. (1998) Campath-1H monoclonal antibody in therapy for previously treated low grade non-Hodgkin's lymphoma: a phase II multicenter study. Journal of Clinical Oncology, 16, 32573263.
  • McLaughlin, P., Hagemeister, F.B. & Grillo-Lopez, A.J. (1999) Rituximab in indolent lymphoma: the single-agent pivotal trial. Seminars in Oncology, 26, 7987.
  • Maloney, D.G. (1999) Preclinical and phase I and II trials of rituximab. Seminars in Oncology, 26, 7478.
  • Milpied, N., Vasseur, B., Parquet, N., Garnier, J.L., Antoine, C., Quartier, P., Carret, A.S., Bouscary, C., Faye, A., Bourbigot, B., Reguerre, Y., Stoppa, A.M., Borquart, P., Hurault de Ligny, B., Dubief, F., Mathieu-Boue, A. & Leblond, V. (2000) Humanised anti-CD20 monoclonal antibody (Rituximab) in post transplant B-lymphoproliferative disorder: a retrospective analysis of 32 patients. Annual Oncology, 11, 113116.
  • Oesterborg, A., Dyer, M.J.S., Bunjes, D., Pangalis, G.A., Bastion, Y., Catovsky, D. & Mellstedt, H. (1997) Phase II multicenter study of human CD52 antibody in previously treated chronic lymphocytic leukemia. Journal of Clinical Oncology, 15, 15671574.
  • Reff, M.E., Carner, C., Chambers, K.S., Chinn, P.C., Leonard, J.E., Raab, R., Newman, R.A., Hanna, N. & Anderson, D.R. (1994) Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood, 83, 435445.
  • Roncella, S., Francia di Celle, P., Cutrona, G., Carbone, A., Sessarego, M., Landonio, G., Foà, R., Rowe, M. & Ferrarini, M. (1993) Cytogenetic rearrangement of C-MYC oncogene occurs prior to infection with Epstein–Barr virus in the monoclonal malignant B cells from an AIDS patient. Leukemia and Lymphoma, 9, 157164.
  • Slaper-Cortenbach, I.C.M., Von Admiraal, L.G., Dem Borne, A.E.G., Van Leeuwen, E.F. & Tetteroo, P.A.T. (1986) Epitope specificity and complement binding studies with monoclonal antibodies (CD9, 10, 24) useful for purging autologous bone marrow grafts of cALL patients. In: Leucocyte Typing III (ed. by A.McMichael), pp. 480484. Oxford University Press, Oxford.
  • Sparano, J.A. (2001) Clinical aspects and management of AIDS-related lymphoma. European Journal of Cancer, 37, 12961305.
  • Stoiber, H., Kacani, L., Speth, C., Wurzner, R. & Dierich, M.P. (2001) The supportive role of complement in HIV pathogenesis. Immunology Reviews, 180, 168176.
  • Tirelli, U., Spina, M., Gaidano, G., Vaccher, E., Franceschi, S. & Carbone, A. (2000) Epidemiological, biological and clinical features of HIV-related lymphomas in the era of highly active antiretroviral therapy. AIDS, 14, 16751688.
  • Tirelli, U., Spina, M., Jaeger, U., Nigra, E., Blanc, P.L., Liberati, A.M., Benci, A. & Sparano, J.A. (2002) Infusional CDE with rituximab for the treatment of human immunodeficiency virus-associated non-Hodgkin's lymphoma: preliminary results of a phase I/II study. Recent Results in Cancer Research, 159, 149153.
  • Wiernik, P.H. (2001) Treatment of human immunodeficiency virus-related lymphoma. Seminars in Hematology, 38, 2731.